Intravenous Immunoglobulin: Mechanism of Action in Autoimmune and Inflammatory Conditions
Jagadeesh Bayry, Eisha Ahmed, Diana Toscano-Rivero, Nicholas Vonnissen, Genevieve Genest, Casey Cohen, Marieme Dembele, Srini Kaveri, Bruce Mazer

To cite this version:
Jagadeesh Bayry, Eisha Ahmed, Diana Toscano-Rivero, Nicholas Vonnissen, Genevieve Genest, et al.. Intravenous Immunoglobulin: Mechanism of Action in Autoimmune and Inflammatory Conditions. The Journal of Allergy and Clinical Immunology: In Practice, 2023, 10.1016/j.jaip.2023.04.002. hal-04088150

HAL Id: hal-04088150
https://hal.sorbonne-universite.fr/hal-04088150
Submitted on 3 May 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Intravenous Immunoglobulin: Mechanism of Action in Autoimmune and Inflammatory Conditions

Jagadeesh Bayry DVM, PhD; Eisha Ahmed BSc, Diana Toscano-Rivero MD, Nicholas Vonniessen BSc, Genevieve Genest MD, Casey Cohen BSc, Marieme Dembele MSc, Srini V. Kaveri DVM, PhD, Bruce D Mazer MD.

1 Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, 75006 Paris, France
2 Department of Biological Sciences & Engineering, Indian Institute of Technology Palakkad, Palakkad 678623, India
3 The Research Institute of the McGill University Health Centre, Translational Program in Respiratory Diseases, and the Department of Pediatrics, McGill University Faculty of Medicine, 1001 Décarie, Montreal, Quebec, Canada H4A 3J1

Corresponding Authors
Drs Bayry and Mazer are co-corresponding authors.

Jagadeesh Bayry, INSERM, Centre de Recherche des Cordeliers, 75006 Paris, France; Department of Biological Sciences & Engineering, Indian Institute of Technology Palakkad, Palakkad 678623, India. Phone: 00 91 4923-226 451; E-mail: Jagadeesh.bayry@crc.jussieu.fr or bayry@iitpkd.ac.in

Bruce D Mazer, The Research Institute of the McGill University Health Centre, Translational Program in Respiratory Diseases, and the Department of Pediatrics, McGill University Faculty of Medicine, 1001 Décarie, Montreal, Quebec, Canada H4A 3J1. Phone: 514-934-1934 E-mail: Bruce.mazer@mcgill.ca
Abbreviations

IVIG Intravenous Immunoglobulin
KD Kawasaki Disease
ITP Immune thrombocytopenic purpura
GBS Guillain–Barré syndrome GBS,
CIDP Chronic inflammatory demyelinating polyneuropathy
SLE Systemic lupus erythematosus
CIA Collagen Induced Arthritis
IL Interleukin
PBMC Peripheral blood mononuclear cells
DC Dendritic cells
pDC Plasmacytoid dendritic cells
EAE Experimental Autoimmune Encephalitis
MISC Multisystemic Inflammatory Syndrome in Children
NET Neutrophil extracellular traps

Key words: Intravenous immunoglobulin, inflammation, autoimmunity, innate immunity, adaptive immunity, Regulatory T cells, IVIG
Clinical Commentary: JACI in practice

Abstract: IVIG is the mainstay of therapy for humoral immune deficiencies and numerous inflammatory disorders. Although the use of IVIG may be supplanted by several targeted therapies to cytokines, the ability of polyclonal IgG to not only act as an effector molecule but as a regulatory molecule is a clear example of the polyfunctionality of IVIG. This article will address the mechanism of action of IVIG in a number of important conditions that are otherwise resistant to treatment. In this commentary we will highlight mechanistic studies that shed light on the action of IVIG. This will be approached by identifying effects that are both common and disease specific, targeting actions that have been demonstrated on cells and processes that represent both innate and adaptive immune responses.
Introduction

IgG plays multiple roles in the immune system. Best known as an effector molecule in host defense, infusions of polyclonal IgG have been employed as the mainstay of treatment for patients with immunodeficiency diseases affecting the humoral immune system. Preparations of human IgG are available for intravenous (IVIG) or subcutaneous (SCIG) administration, which has allowed individuals with both primary and secondary immune defects to achieve much improved outcomes.\(^1\) In addition, IVIG has been employed as a regulator of a large number of autoimmune and inflammatory conditions since the 1980’s\(^2\). IVIG contains a broad spectrum of antibodies, as it is fractionated from plasma pools that include several thousand donors or more\(^3\). IVIG has been consistently and successfully used for numerous conditions, including Immune thrombocytopenic purpura (ITP), Kawasaki Disease (KD), Guillain–Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), systemic lupus erythematosus, dermatomyositis, and other autoimmune and neurologic disorders\(^4\). Indeed, the number of conditions for which IVIG is used “off label” outnumbers those that have regulatory approval\(^5,6\). However, pressures on the plasma fractionation system leading to shortages of raw materials for IVIG, particularly during the recent pandemic period, demand that practitioners carefully scrutinize their use and employ caution both in prescribing, and in over-rationing this essential therapy, to the detriment of patients with primary antibody immune deficiency\(^7\). More thorough mechanistic understanding of the role of IVIG as an immune regulator can provide better rationale and determine the optimal use for this increasingly scarce resource.

IVIG has been used in two distinct dose regimes: low-dose (400-800 mg/kg) replacement therapy in primary immunodeficient patients and high-dose (1-2 g/kg) in autoimmune and inflammatory diseases.\(^1\) As IVIG contains antibodies to diverse pathogens, the main goal of low-dose replacement therapy is to prevent recurrent infections in primary immunodeficient patients or in patients with recurrent infections with secondary immunoglobulin deficiencies. Several lines of evidence also suggest that low-dose IVIG
therapy can exert positive effects on the cellular immune compartment, depending on underlying immunodeficiency\textsuperscript{8-12}. In contrast, most autoimmune conditions require high dose therapy. As will be discussed below, this is likely due to the need for specialized antibody contents that represent a small percentage of pooled IVIG, such as anti-idiotype antibodies, fractions that have specific glycosylation, and other components\textsuperscript{2}.

Autoimmune and inflammatory diseases are characterized by perturbed immune tolerance and aberrant activation of immune and nonimmune cells, inflammation, and tissue damage. Despite the significant number of novel, biological therapies that target cytokines and small-molecule inhibitors aimed at signaling pathways, IVIG continues to have an important therapeutic niche in these diseases. The rationale behind the extensive use of IVIG is due to a combination of relatively low therapeutic toxicity\textsuperscript{13,14} with a very broad spectrum of immunoregulatory actions.

IgG molecules are complex glycoproteins, structured to both interact with target antigens via their variable regions, and with cells that express Fc receptors via their constant regions (Figure 1). These are complemented by multiple glycosylation sites which increase the mobility of the molecule and mediate interaction between IgG and lectin receptors on cells in the immune system. As demonstrated in Figure 1, IVIG has been implicated in multiple critical immune processes that can mitigate inflammatory responses in autoimmune diseases. These actions encompass both the innate and adaptive immune systems. In this commentary we will address several of the key mechanisms of action which can provide direction for the continued use of IVIG and assist in potentially developing therapeutic substitutes for this critical therapy.

\textbf{IVIG modulates structural cells}
Structural cells like epithelial cells, fibroblasts and endothelial cells express a wide range of immune genes and respond to the inflammatory stimuli. Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome are rare severe skin reactions, in most cases triggered by medications, with high morbidity and mortality of up to 40% for TEN. IVIG is one of several therapies, utilized after corticosteroids, which have been shown to improve outcomes, reduce hospital stays and decrease time for the skin to heal. The therapeutic benefits of IVIG in TEN is suggested to be due to inhibition of Fas-mediated keratinocyte death. A different mechanism is seen in experimental models of bullous pemphigoid, an autoimmune blistering disease, for which IVIG suppressed inflammatory cytokines like IL-6 from keratinocytes. In pathologies associated with fibrosis such as systemic lupus erythematosus and Sjögren’s syndrome, IVIG therapy may reverse fibroblast proliferation, and also inhibited early fibrogenic changes in experimental models of Systemic Sclerosis. Endothelial cells function as a barrier between the bloodstream and tissue. They actively contribute to inflammatory processes by secretion of cytokines and chemokines, and by regulating the adhesion and mobility of various immune cells. By activating mitochondrial apoptotic signalling pathways, IVIG induced apoptosis of TNF-α-stimulated umbilical vein endothelial cells. IVIG inhibited TNF-α-induced activation of NF-κB and as a consequence inhibited inflammatory cytokine-mediated proliferation of endothelial cells, and expression of adhesion molecules, inflammatory cytokines and chemokines. Similarly, in a murine model of stroke, IVIG suppressed ischemia-induced enhancement of markers of endothelial cell adhesion and lymphocyte infiltration. IVIG can inhibit inflammatory processes of endothelial cells via specific antibodies in its repertoire that interact with target molecules. Specifically, anti-IL-1α IgG antibodies in IVIG have been shown to inhibit IL-1α-mediated activation of endothelium and consequently, reduce neutrophil adhesion. In a murine
model of antiphospholipid antibody syndrome, IVIG inhibited antiphospholipid antibodies-induced endothelial cell activation and thrombosis in vivo\textsuperscript{20}. IVIG also increased HLA-DR expression in endothelial cells, decreased IL-6 and promoted endothelial cell amplification of Treg cells, all of which may assist in maintenance of allograft tolerance \textsuperscript{30}. Thus, by targeting endothelial cells, IVIG not only reduces endothelial cell function but also mitigates the influx of immune cells to sites of inflammation.

**Innate immunity and IVIG**

The innate immune compartment, including soluble factors such as complement molecules and innate immune cells, plays a key role in the initiation and propagation of pathogenic immune responses through the secretion of inflammatory mediators like cytokines and chemokines, recruiting effector cells, mediating T cell differentiation and programming, and by causing tissue damage. Innate immune cells include antigen presenting cells such as dendritic cells (DC), monocyte/macrophages; NK cells, and granulocytes like neutrophils, eosinophils, and basophils. IVIG actively regulates several key components of the innate immune system.

**IVIG and complement pathways**

The complement pathway is composed of a complex network of proteins that interact with each other in a sequential manner to produce a variety of biological responses. Well known for its crucial role in host defense against infections, the complement pathway also contributes to a range of diseases. IVIG contains antibodies that exert complement scavenging effects\textsuperscript{27,31-33}. By interacting with C3b complement components and preventing the binding of activated C3 to C5 convertase, IVIG inhibited the deposition of C5b-C9 membrane attack complexes on endomysial capillaries, restoring the capillary network and reducing microvasculopathy, a characteristic feature of dermatomyositis\textsuperscript{31}. Another report showed that IVIG diminished complement amplification in dermatomyositis patients by reducing the
concentration of C3 convertase precursors in blood. In both dermatomyositis and KD patients, IVIG therapy suppressed expression of multiple genes for complement products and their receptors.

In a murine model of stroke, IVIG protected against experimental stroke by scavenging C3b and preventing complement-mediated neuronal cell death. IVIG also neutralized anaphylatoxins C3a and C5a, and suppressed their effector functions both in vitro and in vivo animal models. Thus, IVIG exerts diverse actions on the complement system to attenuate inflammation.

Monocytes/Macrophages and Dendritic cells:

IVIG inhibited activation of monocytes and macrophages both in mice and humans, and induced anti-inflammatory cytokines like IL-1 receptor antagonist (IL-1RA), TGF-β and IL-10. IVIG induced Fas-mediated apoptosis of innate cells and neutralized various innate inflammatory cytokines by virtue of high-affinity anti-cytokine IgG antibodies. IVIG also promoted an expansion of monocytic myeloid-derived suppressor cells. Interestingly, induction of IL-10 by IVIG in TLR-4 activated monocytes is dependent on FcγRI (CD64) and FcγRIIb (CD32B), and is impaired in high affinity genetic FCGRIIA risk variants (H131R polymorphism, rs1801274).

The effect of IVIG therapy on monocytes may be a biomarker in KD. Single cell RNA sequencing-based profiling of PBMCs from acute KD patients revealed that monocytes are the major source of inflammatory mediators in these patients. IVIG therapy reduced CD14+ monocytes/macrophages and CD16+ positive inflammatory monocytes in circulation, as well as expression of calgranulin genes and high affinity FcγRI receptors. Microarray data confirmed that IVIG therapy downregulated MAPK14, TLR5 and MYD88, the signaling and adapter proteins involved in TLR and IL-1 receptor signaling which affects multiple signal transduction pathways. In line with these observations, analyses of M1 (inflammatory macrophages which cause tissue damage) and M2 (regulatory...
macrophages which induce tissue repair) macrophages in KD patients revealed that during acute phases of the disease, transcripts of both M1 and M2 markers were increased, then declined following IVIG therapy. IVIG mediated epigenetic regulation of target genes in macrophages via hypermethylation of CpG sites at its promoter region.

DC are the major professional antigen presenting cells which direct both immune tolerance and primary and memory T-cell responses. IVIG suppressed expression of DC co-stimulatory molecules CD40, CD80 and CD86, and HLA-DR in vitro, leading to a tolerogenic DC phenotype. Adoptive transfer of IVIG-treated CD11c+ DC led to amelioration of ITP in mouse. IVIG therapy in CIDP patients reduced levels of inflammatory CD16+ myeloid DC, and reduced inflammatory cytokines like IL-12 and TNF, while enhancing IL-10. IL-10 was also induced by IVIG in two myeloid DC subsets in KD patients in the subacute phase of recovery. IVIG suppressed IFNα production in pDC via two mechanisms: in SLE patients, IVIG inhibited FcγRIIa and IFNα production induced by SLE immune complexes; additionally IVIG contained F(ab')2 residues which induced PGE2 in monocytes, leading to suppression of TLR-7 or TLR-9 agonist-induced IFNα production.

Initial reports on successful clinical use of Fc fragments of IVIG for the treatment of ITP suggested that IVIG blocked Fcγ receptors and hence prevented immune complex-mediated activation of innate immune cells. Subsequent studies, particularly in experimental animal models, reported that terminal α2,6-sialic acid-linked residues on the Fc portion of IgG may mediate some of these immunoregulatory functions of IVIG (Figure 1), suggesting possible enrichment of IgG preparations for sialic acid containing fractions, and thus more targeted usage. However, the importance of the α2,6-sialic acid linked residues appears to be disease and possibly model specific. Murine studies suggest that the α2,6-sialic acid portion of IVIG enhances the inhibitory FcγRIIb in effector splenic macrophages. α2,6-sialic acid linkages may induce IL-33 in marginal-zone macrophages via SIGN-R1 signaling (or in
IL-33 activates basophils via the ST2 receptor to induce IL-4 \(^{63,64}\) which in turn enhances FcγRIIb expression on effector splenic macrophages. Several animal models such as K/BxN-induced arthritis, experimental autoimmune encephalomyelitis (EAE), ITP and experimental allergic bronchopulmonary aspergillosis (ABPA) have validated the requirement of sialylated Fc region or sialylated IgG in imparting protective effects \(^{61,63-69}\). In allergic airways disease, a second sialic acid receptor, DCIR, was shown to mediate the effects of sialylated IgG in abrogating airway inflammation\(^70\).

In contrast, models of autoimmune diseases such as K/BxN serum transfer arthritis, collagen-induced arthritis (CIA), ITP and EAE reported that neither sialylation of Fc fragments nor FcγRIIb are mandatory for the anti-inflammatory effects of IVIG \(^{71-74}\).

In human studies have also not been as conclusive. Flow cytometry and cellular surface plasmon resonance imaging did not find evidence to support CD23 or DC-SIGN as receptors for human IgG irrespective of glycosylation properties on F(ab')\(_2\) or Fc\(^75\). Both FcγRIIb or Fc-sialylation were dispensable for IVIG to inhibit IgG-mediated phagocytosis by human macrophages \(^76\). Although IL-33 was induced by IVIG in autoG-mediatedin patients, it was not produced by DC-SIGN\(^+\) innate cells \(^77\). IL-33 did not induce activation of human basophils nor production of IL-4\(^78\), suggesting that the action of IVIG modulating human basophils would be via different mechanisms. Sialic acid moieties on IgG were also not required for activation of the Wnt/β-catenin pathway, autophagy and immune complex-mediated induction of type I IFN by human pDC\(^{57,79,80}\). DC-SIGN on human monocyte-derived DC played a key role in inducing COX-2-mediated PGE\(_2\) production and regulatory T cell (Treg) expansion\(^81\). But unlike mice, interaction with DC-SIGN was mediated by F(ab')\(_2\) fragments rather than Fc, suggesting that either sialic acid molecules on Fab or anti-DC-SIGN IgG antibodies could mediate these effects. More work is needed to define the role of sialylated Fc fragments in mediating immunoregulatory functions of IVIG.

### Granulocytes:


**Neutrophils:** Neutrophils have a role in inflammatory diseases such as KD through recruiting other innate immune cells to the site of inflammation, secreting inflammatory mediators and causing tissue damage. IVIG therapy exerted cytotoxic effects on neutrophils in KD patients\(^{82,83}\) possibly through anti-Fas and anti-Siglec9 IgG via caspase-dependent and caspase-independent pathways, respectively\(^{84}\). IVIG also reduced neutrophil nitric oxide in KD patients\(^{85}\). In multisystem inflammatory syndrome in children (MIS-C)\(^{86}\), IVIG targeted IL-1\(\beta^+\) neutrophils via PI3K- and NADPH oxidase-dependent cytotoxicity, and suppressed their activation\(^{82}\). IVIG inhibited neutrophil extracellular trap (NET) formation in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis \(in vivo\)\(^{87}\). This may be due to IVIG inducing lactoferrin in neutrophils that negatively regulates NET formation\(^{87,88}\).

The immunoregulatory role of IVIG on neutrophils goes beyond cytotoxicity. In a mouse model of sickle cell disease, IVIG interfered with recruitment of neutrophils in inflamed venules by increasing rolling velocity of granulocytes and reducing adhesion to venules\(^{89}\). Using a neutrophil-mediated acute vascular injury model the effect of IVIG on neutrophil adhesion and activation was dependent on Fc\(\gamma\)RIII via recruitment of SHP-1\(^{90}\).

**Basophils:** IVIG induces the activation marker CD69 as well as IL-4 and other cytokines in IL-3-primed human basophils via F(ab\(^{-}\))- and Syk-dependent mechanisms by interacting with surface-bound IgE\(^{78}\). Induction of CD69 was also observed in IVIG-treated myopathy patients\(^{78}\). IL-4 produced by basophils might dampen inflammation by enhancing Fc\(\gamma\)RIIb and antagonizing Th1 and Th17.

**Eosinophils:** IVIG induces ROS-dependent cytotoxic effects on eosinophils in the presence of inflammatory cytokines both by caspase-dependent and caspase-independent pathways, via anti-Siglec-8 IgG\(^{91}\). IVIG therapy in Churg-Strauss syndrome patients decreased CD69\(^{+}\) activated eosinophils\(^{92}\).
suggesting functional anti-Siglec-8 IgG-mediated cytolysis. Similarly, in moderate to severe childhood atopic dermatitis patients, IVIG therapy caused a decline in peripheral blood eosinophil counts93.

Other positive effects of IVIG on eosinophils have also been observed. Eosinophil levels are frequently significantly higher in KD patients compared to control subjects94. In work by Kuo et al, IVIG therapy induced IL-5 and elevated eosinophil counts, which were positively correlated with successful IVIG therapy95. Mechanistically, increased IL-5 (or other eosinophil chemotactic factors) without increased eosinophil activation factors was correlated with post-IVIG therapy eosinophilia96 and mitigated Th1 inflammation. Th2 cytokines following IVIG therapy were proposed to also help decrease coronary artery lesions.

**Natural Killer cells:**

Classically known for their ability to kill malignant and virus-infected cells by cytotoxic effects, Natural Killer (NK) cell activation also leads to secretion of pro-inflammatory cytokines. IVIG inhibits direct cytotoxicity and ADCC function of human NK cells in vitro97 associated with apoptotic cell death in CD56dim NK cells98. Reduced NK cell function following IVIG therapy was reported in ITP99, CIDP100,101, and KD, all associated with reduced cytotoxic CD56dim NK cell subsets, while preserving or increasing regulatory CD56bright NK cells101,102.

Some women with multiple high-risk pregnancies have elevated preconception peripheral NK cells; trials of IVIG therapy significantly improved the delivery birthweight of babies born to women with high risk of low birthweight infants103. A murine model of recurrent pregnancy loss was associated with increased CD44bright NK cells; IVIG reduced spontaneous abortion rates while suppressing increases in the CD44bright NK cell subset104. Women with recurrent spontaneous abortion similarly display increased NK cells but exhibit reduced NK cell cytotoxicity; IVIG therapy significantly increased the live birth rate105-
as well as increasing expression of inhibitory receptors and decreased activating receptors of NK cells. Further detailed investigation on the regulation of NK cells by IVIG is needed.

**Adaptive Immunity: Human studies**

*Treg/Th17 axis:* CD4⁺ T cells are heterogeneous and various subsets have been identified. Tregs are necessary for the control of inflammation, while, aside from controlling infection, Th1, Th2 and Th17 cells can promote tissue damage, and are associated with autoimmunity. Early studies indicated that IVIG therapy balances Th1 and Th2 cells. Experimental studies have further reported that IVIG suppressed the differentiation, expansion and function of human Th17 cells in an F(ab’)₂-dependent manner by inhibiting STAT-3 phosphorylation. KD has been a paradigm for understanding the role of IVIG in the Treg/Th17 axis. While Th17 cells, as well as cytokines IL-17, IL-22, and IL-23, can be elevated in acute KD, these cytokines were downregulated up to eight weeks following IVIG therapy. Analyses of mRNA in a group of KD subjects revealed that there were no significant changes in the frequency of Th17 cells before and after IVIG therapy; however, Treg-related IL-10 and FoxP3 levels increased 3 days after IVIG, and plasma IL-17 levels significantly decreased after 3 weeks. Single-cell RNA sequencing has also demonstrated increased *FOXP3* mRNA levels after IVIG treatment. Franco et al. found that two weeks after IVIG therapy, KD patients without coronary artery lesions presented an expansion of a Treg population that produced IL-10 and low amounts of IL-4 but no TGF-β. In contrast, patients with arterial inflammation did not exhibit this profile, reinforcing the idea that Tregs are key for controlling the vascular inflammation and may be associated with KD resolution. Additionally, two myeloid DC subsets (CD14⁺ cDC2 and ILT-4⁺ CD4⁺ tmDC) from KD patients internalized IgG in vitro through FcγR, secreted IL-10 and expanded Fc-specific Tregs.
The effects of IVIG on Treg are not restricted to KD. Women with recurrent pregnancy loss (RPL), ITP patients successfully treated with IVIG, or ex vivo IVIG-treated healthy donor T cells, showed increased Tregs as well as enhanced in vitro Treg activation and increased suppressive function\textsuperscript{35,116-118}. In GBS patients, IVIG reciprocally regulated Th1/Th17 and Tregs\textsuperscript{119} suggesting that Treg frequency represents a potential immunological biomarker to predict clinical response to IVIG therapy\textsuperscript{120}. Similarly, patients with CIDP and dermatomyositis showed increased frequency of Tregs following IVIG\textsuperscript{102}. In vitro stimulation with IVIG of PBMC from GBS patients resulted in increased in vitro secretion of IL-10 and TGF-β\textsuperscript{121} and expansion of Tregs\textsuperscript{121}. Reduced frequency of circulating Tregs in myasthenia gravis was corrected by IVIG and induced expansion of circulating CD4\textsuperscript{+}CD25\textsuperscript{+}FoxP3\textsuperscript{+} and CD4\textsuperscript{+}CD25\textsuperscript{+}FoxP3\textsuperscript{+} CTLA-4\textsuperscript{+} T cells.

**B cells and humoral antibody responses:**

Potential mechanisms through which IVIG regulates the humoral immune system include the (i) neutralization of pathogenetic autoantibodies via anti-idiotype antibodies\textsuperscript{122}, (ii) acceleration of the catabolism of pathogenic autoantibodies by saturation of FcRn\textsuperscript{123}, (iii) interaction with inhibitory Fc receptors, (iv) the reset of immunoglobulin repertoires\textsuperscript{124}, and (v) inhibition of activation and proliferation of B-cells by recruiting phosphatases\textsuperscript{125,126}.

IVIG suppressed B-cell activation and proliferation through agonistic binding to inhibitory receptors such as CD22 and FcγRIIb, while antagonizing signaling through BCR or TLRs\textsuperscript{126}, although this is not a consistent finding in human B-cells\textsuperscript{105}. Compared to healthy controls, patients with CIDP display reduced expression of FcγRIIb on the surface of naïve and memory B-cells; this can be rescued following treatment with IVIG, resulting in upregulation of FcγRIIb on both B-cell subsets\textsuperscript{124}. Treatment of GBS
with IVIG promoted rapid expansion of plasmablasts one week after onset of treatment\textsuperscript{124}. In addition, IVIG may reduce B-cell survival by neutralization of BAFF, as demonstrated in CIDP patients\textsuperscript{127,128}.

**Adaptive Immunity: Murine studies**

Using a collagen induced arthritis (CIA) model, it was demonstrated that IVIG affected T-cell and germinal center responses\textsuperscript{129}, and that IVIG-mediated attenuation of CIA was IL-10 dependent and associated with increased frequencies of Tregs and decreased Th17 in the spleen, coupled with a decrease in splenic germinal center B- and T-follicular helper (Tfh) cells. Further, IVIG attenuates murine allergic airways disease (AAD) by inducing highly suppressive antigen specific Tregs\textsuperscript{130-132}. This entails modification of DC and is driven at least in part by Fe-sialic acid residues\textsuperscript{70,130,133}. IgG-derived Tregitopes (T-regulatory epitopes), which can be produced synthetically\textsuperscript{134}, can reproduce the effects of IVIG in allergic airways disease\textsuperscript{135}. IVIG had a positive effect on proliferation of natural Tregs\textsuperscript{136} and reciprocally regulated pathogenic Th1/Th17 in experimental models of autoimmune diseases like EAE by regulating T-cell trafficking\textsuperscript{73}; this effect was independent of IgG sialylation\textsuperscript{74}. Other mechanisms including modulation of prostaglandin E2 have been reported by which IVIG induces and/or expands Tregs\textsuperscript{70,81,134}.

Anti-idiotype antibodies are naturally occurring antibodies against various molecules including normal cytokines, receptors and pathogenic autoantibodies; anti-idiotype antibodies in IVIG may help in regulating inflammatory responses. From as early as 1984, with the discovery of anti-idiotypic antibodies in IVIG against idiotypes of anti-VIII autoantibodies, multiple candidate anti-idiotypic antibodies have surfaced as highly relevant molecules\textsuperscript{52,122,137-139}. For example, anti-anti-citrullinated-protein antibodies fractionated from commercial IgG (ACPA-sIVIG) was as effective as high-dose IVIG at Treg induction, reduced anti-collagen and anti-ACPA antibody responses, increased anti-inflammatory cytokine (IL-10 and TGF-β), and decreased pro-inflammatory cytokine (TNFα and IL1β) production in the CIA model\textsuperscript{140}. Similarly, another study showed that anti-anti- β2GPI specific fraction of IVIG, was highly effective
at preventing fetal loss and repairing fecundity in mice with experimental antiphospholipid syndrome (APS). These studies provide insight into the need to understand potential bioactive fractions within normal human immune globulin that can mitigate disease.

**Conclusion**

There has been extensive mechanistic study in animal models of disease and observation in IVIG-treated individuals. In this clinical commentary, we addressed pertinent studies that provide clues to biomarkers that track the effects of IVIG in autoimmune and inflammatory conditions. IVIG therapy can be best utilized if there will be clearer guidance for ancillary measures of immunological effectiveness to complement clinical observations. To summarize over 30 years of use of this therapy in a brief commentary does not do justice to the extensive amount of work that has been performed. However, the take home message is that there has been significant animal and human study of IVIG mechanistic biomarkers that we can use for clinical application. For example, measuring monocyte subsets or NK cells, as has been demonstrated in KD, in arthritis models and in high-risk pregnancies, may give practitioners more information regarding the likelihood of treatment success. Moreover, the accumulated evidence on induction of Tregs by IVIG suggests that there is a role for monitoring Treg in patients for whom there are questions on the effectiveness of IVIG therapies; this could be a target for validation in larger cohorts. Considering IVIG as a scare resource argues for development of distinct guidelines not simply for disease indications, but for baseline evaluation and follow-up of individuals who have IVIG therapy initiated for autoimmune and inflammatory diseases. This will not only provide a method of monitoring success or failure of therapy but will allow for accrual of evidence that can advance the care of those who are treated with human immunoglobulin.

Further mechanistic study will also improve the chances of understanding various fractions of IVIG that have specific bioactivity. The study of sialic acid linkages may address a need for a fraction of IgG that
can target specific conditions, but it also has increased the sophistication of preparation of other antibody therapies, which require proper glycosylation to have maximum effect. Other modalities such as Tregitopes or anti-idiotype antibodies such as targeted anti-endothelial antibodies, as examples, can reduce reliance on the plasma supply. Until such time as a true substitute is found through clinical trials, IVIG will continue to be a mainstay of therapy for multiple autoimmune conditions.
References


doi:10.1007/s00210-012-0765-8


Figure Legend:

Figure 1: The current knowledge on the implication of either F(ab’)_2, Fc or both in the mechanisms of action of IVIG. IgG contain Fab and Fc regions. Several mechanisms of IVIG are mediated by F(ab’)_2 fragments. Some of the Fc-mediated functions also implicit the involvement of α2,6-sialic acid linkages at Asn297. However, mechanisms of IVIG for dendritic cells, various T cell subsets and B lymphocytes are dependent on both F(ab’)_2 and Fc fragments. V_H, heavy chain variable domain; V_L, light chain variable domain; C_H, heavy chain constant domain; C_L, light chain constant domain. Figure created in BioRender.com.
- Complement scavenging
- Neutralization of pathogenic IgG
- Cytokine neutralization
- Human basophil activation and IL-4 induction
- Cytotoxic effects on human neutrophils, eosinophils, monocytes, lymphocytes
- Interaction with specific cellular receptors
- Autophagy in immune cells

- FcRn saturation
- Blockade of FcγRs
- Functions dependent on the Asp297-linked α2,6 sialylated glycans like enhancement of FcγRIIb on effector macrophages

- Regulation of dendritic cells and macrophage functions
- Inhibition of Th1/Th17 responses
- Expansion of regulatory T cells
- Inhibition of B cell activation
- Cytotoxic effects on NK cells
- Regulation of endothelial cell functions
Table 1: Landmark studies on the mechanisms of action of IVIG

<table>
<thead>
<tr>
<th>Innate Immune Compartment</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blockade of Fcγ receptors</td>
<td>Debré et al. 1993\textsuperscript{58}</td>
</tr>
<tr>
<td>Induction of apoptosis of immune cells by Fas apoptosis pathway</td>
<td>Prasad et al. 1998\textsuperscript{142}</td>
</tr>
<tr>
<td>Induction of anti-inflammatory IL-1 receptor antagonist (IL-1RA) in monocytes</td>
<td>Ruiz de Souza et al. 1995\textsuperscript{36}</td>
</tr>
<tr>
<td>Suppression of an array of immune activation genes in monocytes of Kawasaki disease</td>
<td>Abe et al. 2005\textsuperscript{47}</td>
</tr>
<tr>
<td>Regulation of dendritic cell functions</td>
<td>Bayry et al. 2003\textsuperscript{52,55}</td>
</tr>
<tr>
<td></td>
<td>Siragam et al. 2006\textsuperscript{53}</td>
</tr>
<tr>
<td></td>
<td>Wiedeman et al. 2013\textsuperscript{57}</td>
</tr>
<tr>
<td>Inhibition of NK cytotoxicity</td>
<td>Ruiz et al. 1996\textsuperscript{108}</td>
</tr>
<tr>
<td>Cytotoxic effects on neutrophils by anti-Siglec-9 autoantibodies</td>
<td>von Gunten et al. 2006\textsuperscript{64}</td>
</tr>
<tr>
<td>Inhibition of neutrophil extracellular trap (NET)</td>
<td>Uozumi et al. 2020\textsuperscript{87}</td>
</tr>
<tr>
<td>Cytotoxic effects on eosinophils by anti-Siglec-8 autoantibodies</td>
<td>von Gunten et al. 2007\textsuperscript{91}</td>
</tr>
<tr>
<td>IL-3-dependent induction of human basophil activation and IL-4 secretion via anti-IgE IgG</td>
<td>Galeotti et al. 2019\textsuperscript{78}</td>
</tr>
<tr>
<td>Fc-Sialylation-dependent anti-inflammatory mechanisms in Mice</td>
<td>Kaneko et al. 2006\textsuperscript{61}</td>
</tr>
<tr>
<td></td>
<td>Anthony et al. 2011\textsuperscript{63}</td>
</tr>
<tr>
<td></td>
<td>Fiebiger et al. 2015\textsuperscript{64}</td>
</tr>
<tr>
<td>Identification of receptors for sialylated Fc fragments of IgG</td>
<td>Anthony et al. 2008\textsuperscript{143}</td>
</tr>
<tr>
<td></td>
<td>Séité et al. 2010\textsuperscript{126}</td>
</tr>
<tr>
<td></td>
<td>Massoud et al. 2014\textsuperscript{70}</td>
</tr>
<tr>
<td></td>
<td>Fiebiger et al. 2015\textsuperscript{64}</td>
</tr>
<tr>
<td>Induction of inhibitory ITAM signaling through FcγRIII</td>
<td>Aloulou et al. 2012\textsuperscript{144}</td>
</tr>
<tr>
<td>Induction of autophagy in innate immune cells</td>
<td>Das et al. 2020\textsuperscript{87}</td>
</tr>
<tr>
<td>Epigenetic regulation of macrophages</td>
<td>Guo et al. 2020\textsuperscript{51}</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Innate Immune Compartment</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regulation of Th1/Th2 balance</td>
<td>Graphou et al. 2003\textsuperscript{111}</td>
</tr>
<tr>
<td>Inhibition of Th17 differentiation, expansion and function</td>
<td>Maddur et al. 2011\textsuperscript{112}</td>
</tr>
<tr>
<td>Enhancement of regulatory T cells</td>
<td>Kessel et al. 2007\textsuperscript{118}</td>
</tr>
<tr>
<td></td>
<td>Ephrem et al. 2008\textsuperscript{136}</td>
</tr>
<tr>
<td>Reciprocal regulation of Th17/Treg cells</td>
<td>Othy et al. 2013\textsuperscript{73}</td>
</tr>
<tr>
<td></td>
<td>Lee et al. 2014\textsuperscript{129}</td>
</tr>
<tr>
<td></td>
<td>Guo et al. 2015\textsuperscript{114}</td>
</tr>
</tbody>
</table>
| Identification of mechanisms of Treg expansion in human and mouse | De Groot et al. 2008 134  
| | Trinath et al. 2013 81  
| | Massoud et al. 2014 70  
| | Fiebiger et al. 2015 64  
| Suppression of IL-4- and CD40-induced B-lymphocyte activation | Zhuang et al. 2002 125  
| Inhibition of TLR9 signaling by recruiting phosphatases | Séité et al. 2011 126  
| **Soluble/Humoral Factors** | **References**  
| Neutralization of pathogenic autoantibodies by anti-idiotype antibodies | Sultan et al. 1984 122  
| Neutralization of various cytokines by virtue of high-affinity anti-cytokine IgG antibodies | Svenson et al. 1993 42  
| Complement scavenging effects | Basta and Dalakas. 1994 31  
| | Basta et al. 2003 33  
| **Structural Cells** |  
| Modulation of endothelial functions | Xu et al. 1998 25  
| Inhibition of toxic epidermal necrolysis by blockade of Fas-mediated keratinocyte death | Viard et al. 1998 18  
| Saturation of FcRn | Akilesh et al. 2004 123  
| Modulation of immunoregulatory or structural muscle genes in the patients with inflammatory myopathies | Raju and Dalakas 2005 34  
